<DOC>
	<DOC>NCT01836120</DOC>
	<brief_summary>A study of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with Gastric Cancer.The purpose of this study is to compare the activity of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with gastric carcinoma by estimating progression free survival (PFS) in each treatment arm.</brief_summary>
	<brief_title>A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>1. Signed informed consent form 2. Performance Status Eastern Cooperative Oncology Group (ECOG) 02; 3. Histologically or cytologically confirmed gastric cancer; 4. The firstline chemotherapy failure (required containing 5fluorouracil) 5. At least have one measurable disease(according to RECIST, Response Evaluation Criteria in Solid Tumors ) 6. Life expectancy of at least 3 months; 1. Received any prior treatment including Raltitrexed; 2. Active or uncontrolled infection; 3. Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; 4. Pregnant or lactating women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>second-line chemotherapy</keyword>
	<keyword>Raltitrexed</keyword>
</DOC>